TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23406672

Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg thrice daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 70
Study: 21836046

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body weight)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study: 18394731

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 3605
Study: 17309402

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome present at baseline
Number of subjects: 2123

Group type: COMPARATOR
Intervention: Normal blood glucose levels at baseline
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Elevated fasting glucose level
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Diabetes family history
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol level < 1.0 mmol/L
Number of subjects: 2123
Study: 15121405

Group type: EXPERIMENTAL
Intervention: Olpadronate (10 mg/m2 daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 14644967

Group type: EXPERIMENTAL
Intervention: Nurse led smoking cessation intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 240
Study: 9745100

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E2
Number of subjects: 130

Group type: COMPARATOR
Intervention: Extraamniotic prostaglandin F2alpha
Number of subjects: 130
Study: 8017643

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 12
Study: 2806735

Group type: EXPERIMENTAL
Intervention: Inspiratory resistance training using modified computer games for the first six months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inspiratory resistance training using modified computer games for the second six months.
Number of subjects: 0
Study: 31035354

Group type: EXPERIMENTAL
Intervention: Protein-fortified diet (1.8 g/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 40
Study: 28559408

Group type: EXPERIMENTAL
Intervention: Patient navigators included in support networks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Networks without a navigator
Number of subjects: 25

Group type: COMPARATOR
Intervention: Network metrics
Number of subjects: 25
Study: 26317839

Group type: EXPERIMENTAL
Intervention: Aftercare with telephone intervention
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 600
Study: 24043732

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 21741011

Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine
Number of subjects: 70
Study: 19352043

Group type: EXPERIMENTAL
Intervention: Cystine/Theanine (CT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17075318

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1500 mg/m) as a 30‐min intravenous infusion on days 1 and 8, followed by oxaliplatin (130 mg/m) as a 4‐h intravenous infusion on day 8 every 21 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gemcitabine (without oxaliplatin coadministration) on day 1
Number of subjects: 10
Study: 15523163

Group type: EXPERIMENTAL
Intervention: Immediate cleaning with 66% ethyl alcohol (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Daily cleaning with 66% ethyl alcohol (Group D)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No cleaning (Group C)
Number of subjects: 100
Study: 11079436

Group type: EXPERIMENTAL
Intervention: Television series 'Families'
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 56
Study: 10072831

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at a dose of 200 micrograms.d‐1 for 5 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no PGE1)
Number of subjects: 30
Study: 7691117

Group type: EXPERIMENTAL
Intervention: Epirubicin 75 mg/m2 with G-CSF
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2 with G-CSF
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2 without G-CSF
Number of subjects: 18
Study: 6818829

Group type: EXPERIMENTAL
Intervention: Topical timolol with digital ocular compression
Number of subjects: 59

Group type: COMPARATOR
Intervention: Combined acetazolamide-mannitol pre-medication with digital compression
Number of subjects: 59
Study: 31244398

Group type: EXPERIMENTAL
Intervention: Real-world news coverage
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Hypothetical news coverage following CDC recommendations
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (hypothetical coverage not specified)
Number of subjects: 321
Study: 29185930

Group type: EXPERIMENTAL
Intervention: Sourdough-fermented rye crispbread
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Unfermented rye crispbread
Number of subjects: 24

Group type: COMPARATOR
Intervention: Yeast-fermented refined wheat crispbread
Number of subjects: 24
Study: 25394692

Group type: EXPERIMENTAL
Intervention: Diet plus omega-3 supplementation (900 mg/day orally)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Diet alone (control)
Number of subjects: 87
Study: 25764643

Group type: EXPERIMENTAL
Intervention: Intra-operative periarticular injection with multimodal drugs (diclofenac, adrenaline, marcaine, morphine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 22292592

Group type: EXPERIMENTAL
Intervention: Lightweight aluminum cylinders (3.6-lb)
Number of subjects: 22

Group type: COMPARATOR
Intervention: E-cylinders (22-lb)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (lightweight and E-cylinders)
Number of subjects: 22
Study: 19766534

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir for 6 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 100
Study: 17323791

Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg twice daily (BID)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo BID
Number of subjects: 180
Study: 17129838

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 2.250 g
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 12589281

Group type: EXPERIMENTAL
Intervention: Group B (silicone index)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group C (depth gauge bur)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group A (control, freehand approach)
Number of subjects: 30
Study: 10589314

Group type: EXPERIMENTAL
Intervention: Nurse-visited
Number of subjects: 480

Group type: COMPARATOR
Intervention: Paraprofessional-visited
Number of subjects: 480
Study: 7805916

Group type: EXPERIMENTAL
Intervention: Follicular fluid (FF)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Mixtures of peritoneal fluid (PF) and follicular fluid (FF)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Earle's medium (control)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid (PF) alone
Number of subjects: 46
Study: 1826962

Group type: EXPERIMENTAL
Intervention: etanidazole (2.0 g/m2) and pimonidazole (0.75 g/m2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: etanidazole (2.0 g/m2/dose) and pimonidazole (0.75 g/m2)
Number of subjects: 48
Study: 6761288

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine/caffeine
Number of subjects: 201

Group type: COMPARATOR
Intervention: Mazindol
Number of subjects: 201

Group type: COMPARATOR
Intervention: Diethylpropion
Number of subjects: 201
Study: 31483273

Group type: EXPERIMENTAL
Intervention: Kiosk system
Number of subjects: 46

Group type: COMPARATOR
Intervention: Smartphone-based app
Number of subjects: 46
Study: 27993828

Group type: EXPERIMENTAL
Intervention: Filgotinib 50 mg
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 26256300

Group type: EXPERIMENTAL
Intervention: Propofol supplementation in cardioplegia (6 μg/mL)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intralipid (placebo)
Number of subjects: 101
Study: 23721577

Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 50

Group type: COMPARATOR
Intervention: Duraphat varnish
Number of subjects: 50
Study: 21704239

Group type: EXPERIMENTAL
Intervention: CER 30 mg once daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: CIR 10 mg TID
Number of subjects: 36
Study: 19319076

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 20
Study: 17041518

Group type: EXPERIMENTAL
Intervention: Neuracryl M embolization
Number of subjects: 6
Study: 12616370

Group type: EXPERIMENTAL
Intervention: Excision and marsupialization with dressing by bacterial collagenase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Excision and marsupialization without dressing by bacterial collagenase
Number of subjects: 40
Study: 11060533

Group type: EXPERIMENTAL
Intervention: Neonatal metabolic bone disease (evidence of high peak plasma alkaline phosphatase >1200 IU)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Height at 9 to 12 years
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Parental height and pubertal status
Number of subjects: 765
Study: 9360702

Group type: EXPERIMENTAL
Intervention: Recombinant vaccine against hepatitis B virus (HBV)
Number of subjects: 103
Study: 1592065

Group type: EXPERIMENTAL
Intervention: Caffeine (Caf) 250 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 14
Study: 3881177

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 88
Study: 31466614

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 29750365

Group type: EXPERIMENTAL
Intervention: Escalated medical therapy
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 259

Group type: COMPARATOR
Intervention: Prior coronary revascularization
Number of subjects: 259

Group type: COMPARATOR
Intervention: Non-revascularized patients
Number of subjects: 259
Study: 26739248

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25042877

Group type: EXPERIMENTAL
Intervention: Laparoscopic orchiopexy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open orchiopexy
Number of subjects: 46
Study: 22910324

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 85

Group type: COMPARATOR
Intervention: ABC/3TC
Number of subjects: 85
Study: 20575654

Group type: EXPERIMENTAL
Intervention: Natural progesterone (NP) per vagina at 100 mg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Natural progesterone (NP) per vagina at 200 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Natural progesterone (NP) per os at 100 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Natural progesterone (NP) per os at 200 mg/day
Number of subjects: 100
Study: 17661579

Group type: EXPERIMENTAL
Intervention: Right breast pumping
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Left breast pumping
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both breasts pumping
Number of subjects: 35
Study: 16547380

Group type: EXPERIMENTAL
Intervention: Standard amino acid solution with glutamine dipeptide (20% of total amino acids)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard amino acid solution
Number of subjects: 55
Study: 11465341

Group type: COMPARATOR
Intervention: Growth hormone replacement (1 to 2 U GH/day) for 6 months, followed by 2 U GH/day for an additional 6 months.
Number of subjects: 24
Study: 10195069

Group type: EXPERIMENTAL
Intervention: Formoterol (18 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7723001

Group type: EXPERIMENTAL
Intervention: Urn randomization
Number of subjects: 0
Study: 3395542

Group type: EXPERIMENTAL
Intervention: MST 60 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: MST 60 mg and diazepam 10 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: MST 60 mg and hyoscine 0.6 mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 29145527

Group type: EXPERIMENTAL
Intervention: Intraoral scanning (IOS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional impression (CI) taking
Number of subjects: 19
Study: 28617566

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 3,000 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 40
Study: 26069941

Group type: COMPARATOR
Intervention: Insemination
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Induced ovulation (750 IU eCG, 500 IU hCG)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Superovulation (1,500 IU eCG, 1,000 IU hCG)
Number of subjects: 25
Study: 22784488

Group type: EXPERIMENTAL
Intervention: Cerasul bearing
Number of subjects: 250

Group type: COMPARATOR
Intervention: Metasul bearing
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Overall (Cerasul and Metasul)
Number of subjects: 250
Study: 21527594

Group type: EXPERIMENTAL
Intervention: Oral synbiotics (Bifidobacterium, Lactobacillus, and galactooligosaccharides) preoperatively for 14 days and postoperatively for 11 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: No synbiotics (control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oral synbiotics
Number of subjects: 61
Study: 18467280

Group type: EXPERIMENTAL
Intervention: Exercise with prophylactic EPO therapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study: 17518666

Group type: EXPERIMENTAL
Intervention: HYAFF p100 (total benzyl ester of hyaluronan)
Number of subjects: 20

Group type: COMPARATOR
Intervention: HYAFF p80 (partial benzyl ester of hyaluronan)
Number of subjects: 20
Study: 12953793

Group type: EXPERIMENTAL
Intervention: 250 mg of HCA
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 6
Study: 10659113

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (massage with Roman chamomile essential oil)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Massage (massage with carrier oil)
Number of subjects: 103
Study: 8892452

Group type: EXPERIMENTAL
Intervention: 40 Gy total dose extended field radiotherapy (EF‐RT)
Number of subjects: 376

Group type: COMPARATOR
Intervention: 30 Gy total dose extended field radiotherapy (EF‐RT) plus 10 Gy total dose involved field radiotherapy (IF‐RT)
Number of subjects: 376
Study: 1985011

Group type: EXPERIMENTAL
Intervention: Standard meal (Ensure Plus)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg/SL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6607819

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg once daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Naproxen 250 mg twice daily
Number of subjects: 45
Study: 29776112

Group type: EXPERIMENTAL
Intervention: Tensor renormalization group algorithm with randomized singular value decomposition; specific details on dosage and duration not applicable.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oversampling parameter larger than the bond dimension; specific details on dosage and duration not applicable.
Number of subjects: 0
Study: 26836950

Group type: EXPERIMENTAL
Intervention: Quisinostat 12 mg three times weekly
Number of subjects: 26
Study: 24035407

Group type: EXPERIMENTAL
Intervention: Galantamine (target dose 24 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Risperidone (target dose 1.5 mg)
Number of subjects: 100
Study: 22911284

Group type: EXPERIMENTAL
Intervention: Group Exercise Program (GI) - strength, balance, and functional mobility exercises, 50 minutes, twice a week for 4 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stretching Exercises (GC) - 50 minutes, twice a week for 4 months
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation between handgrip strength test and bone mineral density (BMD) of the femoral neck
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Correlation between handgrip strength test and BMD of the total femur
Number of subjects: 36
Study: 20856886

Group type: EXPERIMENTAL
Intervention: Reduction in plasma HIV-1 RNA by 0.74 log(10) copies/mL
Number of subjects: 3381

Group type: COMPARATOR
Intervention: Baseline plasma HIV-1 levels ≥4 log(10) copies/mL
Number of subjects: 3381
Study: 18074146

Group type: EXPERIMENTAL
Intervention: Exponential rebreathing method
Number of subjects: 18

Group type: COMPARATOR
Intervention: Equilibrium rebreathing method
Number of subjects: 18

Group type: COMPARATOR
Intervention: Inert gas rebreathing method
Number of subjects: 18
Study: 16170715

Group type: EXPERIMENTAL
Intervention: Multidetector-row CT (MDCT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intravenous pyelography (IVP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combined unenhanced and excretory phase MDCT
Number of subjects: 59
Study: 12690415

Group type: EXPERIMENTAL
Intervention: 131I-lipiodol therapy with a mean activity of 1.9 GBq (SD 0.2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 131I-lipiodol therapy with potassium iodide (KI) thyroid blocking
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Biological dosimetry using the in vitro micronucleus (MN) assay
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MCNP method for dosimetry
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MIRDOSE method for dosimetry
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall patient dosimetry
Number of subjects: 15
Study: 10479839

Group type: EXPERIMENTAL
Intervention: Surgical tracheostomy (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy (n = 25)
Number of subjects: 50
Study: 8946272

Group type: EXPERIMENTAL
Intervention: 15 mg dexfenfluramine twice daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 2014076

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) 3‐mg pessaries 4 hours apart, followed by oxytocin infusion if necessary
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intravenous oxytocin infusion
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 94
Study: 7171536

Group type: EXPERIMENTAL
Intervention: Consumption of breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omission of breakfast
Number of subjects: 0
Study: 6368424

Group type: EXPERIMENTAL
Intervention: Combination of rifampin (RMP) 600 mg and ethionamide (ETH) 500 mg
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: RMP administered twice a week for three months
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: RMP + ETH
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Daily administration of ETH and DDS or CLO
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Reduction of daily dose of ETH or reduction of duration of RMP + ETH
Number of subjects: 596
Study: 29516257

Group type: EXPERIMENTAL
Intervention: UVA10 (10 J cm(2) for 15 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: UVA20 (20 J cm(2) for 30 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON (no light)
Number of subjects: 10
Study: 27484673

Group type: EXPERIMENTAL
Intervention: 1064-nm laser treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study: 24953021

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Variceal Band Ligation (VBL)
Number of subjects: 64
Study: 22446517

Group type: EXPERIMENTAL
Intervention: Additional weekend physical therapy (PT) and occupational therapy (OT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group received PT and OT Monday to Friday
Number of subjects: 105
Study: 20429041

Group type: EXPERIMENTAL
Intervention: General internists
Number of subjects: 0

Group type: COMPARATOR
Intervention: IM subspecialists
Number of subjects: 0
Study: 18758197

Group type: EXPERIMENTAL
Intervention: OxyContin tablets (controlled‐release oxycodone hydrochloride: 5, 10, 20, and 40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OxyContin tablets
Number of subjects: 0
Study: 15968406

Group type: EXPERIMENTAL
Intervention: Dalteparin (200 IU per kilogram subcutaneously daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 12964131

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (six sessions)
Number of subjects: 108
Study: 10592923

Group type: EXPERIMENTAL
Intervention: Specific Language Impairment group (SLI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 8758083

Group type: EXPERIMENTAL
Intervention: Chloroquine (CHL) 25 mg/kg over 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfadoxine (SDX) 25 mg/kg plus Pyrimethamine (PYR) 1.25 mg/kg (statim dose)
Number of subjects: 0
Study: 1916791

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon (IFN) alpha 2a plus cryotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo injections plus cryotherapy
Number of subjects: 60
Study: 6123343

Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 0
Study: 31744837

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 63276

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) with longer time (>4 years) since initiation
Number of subjects: 63276

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) with higher mean daily dose (>1000 μg fluticasone equivalents)
Number of subjects: 63276

Group type: COMPARATOR
Intervention: No ICS use
Number of subjects: 63276